Jeff Aronin Wins the 2019 BIG Innovation Award for Leadership

The award recognizes the Bioscience Innovation CapitalTM
that Paragon Biosciences contributes to the success of its portfolio of
biopharmaceutical companies

CHICAGO–(BUSINESS WIRE)–Paragon Biosciences Chairman and CEO Jeffrey
S. Aronin
won a 2019 BIG Innovation Award presented by the Business
Intelligence Group. The award honors executives whose leadership
improves quality of life.

“This year’s winners show just how deep a role innovation plays in
nearly every aspect of business,” said Maria Jimenez, chief operating
officer of the Business Intelligence Group. “We are thrilled to be
honoring Jeff Aronin as he is leading by example and making real
progress on improving the daily lives of so many.”

In his therapeutic focus areas, Jeff Aronin’s companies have been among
the most successful at developing
medicines for severe diseases
which previously had no FDA-approved

Paragon Biosciences advances that mission through its contribution of
Bioscience Innovation CapitalTM: For rare and complex
diseases, Paragon analyzes the viability of potential therapies, invests
in new biopharmaceutical companies to further develop promising
treatments, catalyzes the progress of its portfolio companies through
early-incubation services, and provides clinical and regulatory guidance
by a team with a near-perfect track record of first-cycle novel drug

“The Paragon Biosciences team prides itself on our commitment to solving
critical medical needs that are underserved by others,” said Mr. Aronin.
“The BIG Innovation Award is a testament to the Bioscience Innovation
CapitalTM we contribute and my team’s dedication to improving

For 25 years, Mr. Aronin has led and inspired healthcare innovation. The
BIG Innovation Award is just
the latest recognition
of his leadership in the development of novel
therapies. Insights
magazine recently recognized Mr. Aronin as one of the most
influential leaders in healthcare for his extraordinary track record at
improving the quality of life of patients with severe diseases, by
developing breakthrough medicines to treat those conditions.

“The year ahead holds tremendous opportunity for therapy innovation,”
said Mr. Aronin. “In 2019, we plan to make significant investments in
AI-enabled life sciences and advanced genetic therapies.”

About Paragon Biosciences:

For severe and complex diseases, Paragon Biosciences researches the
viability of potential treatments for unmet patient needs, invests in
the development of novel medicines, launches biopharmaceutical companies
to further develop those therapies, and supports these new portfolio
companies with early-incubation services. After which, the portfolio
companies operate independently as they conduct clinical trials and seek
FDA approval of improved treatments. Paragon Biosciences is
headquartered in Chicago, Illinois. For more information, visit:

About Business Intelligence Group:

The Business Intelligence Group was founded with the mission of
recognizing true talent and superior performance in the business world.
The organization’s proprietary and unique scoring system selectively
measures performance across multiple business domains and then rewards
those whose achievements stand above those of their peers.


Rachel Lenke

error: Content is protected !!